Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Sep 14;20(34):12313-21.
doi: 10.3748/wjg.v20.i34.12313.

Abnormal β-catenin immunohistochemical expression as a prognostic factor in gastric cancer: a meta-analysis

Li-Fu Li  1 , Zheng-Jie Wei  1 , Hong Sun  1 , Bo Jiang  1
Affiliations
Review

Abnormal β-catenin immunohistochemical expression as a prognostic factor in gastric cancer: a meta-analysis

Li-Fu Li et al. World J Gastroenterol. .

Abstract

Aim: To evaluate the effect of β-catenin immunohistochemical expression on the prognosis of gastric cancer (GC).

Methods: We searched Pubmed and Embase to identify eligible studies. The search ended on November 10, 2013, with no lower date limit. The citation lists associated with the studies were used to identify additional eligible studies. We included studies reporting sufficient information to estimate the HR and 95%CI, and information to estimate the OR in the analysis of clinicopathological features. The qualities of these studies were assessed using the Newcastle-Ottawa Quality Assessment Scale. HRs and ORs and their variance were calculated and pooled using Review Manager Version 5.2.

Results: A total of 24 studies were identified and comprised 3404 cases. β-catenin expression was significantly correlated with poor overall survival (OS) in GC patients (HR = 1.85, 95%CI: 1.39-2.46), but showed a significant degree of heterogeneity (I (2) = 71%, P < 0.0001). Subgroup analysis indicated that an abnormal pattern of β-catenin expression had an unfavorable effect on OS (HR = 1.79, 95%CI: 1.39-2.32). However, accumulation in the nucleus or loss of membrane did not influence the survival of GC patients independently. Moreover, the combined OR of β-catenin indicated that β-catenin expression was associated with Lauren classification (OR = 1.98, 95%CI: 1.19-3.29), lymph node metastasis (OR = 2.00, 95%CI: 1.44-2.77), distant metastasis (OR = 2.69, 95%CI: 1.35-5.38) and grade of differentiation (OR = 2.68, 95%CI: 1.66-4.34). β-catenin expression did not correlate with TNM stage (OR = 1.34 95%CI: 0.96-1.86), the depth of invasion (OR = 1.48, 95%CI: 0.94-2.33) or vascular invasion (OR = 1.11, 95%CI: 0.70-1.76).

Conclusion: Abnormal β-catenin immunohistochemical expression may be associated with tumor progression and could be a predictive factor of poor prognosis in patients with GC.

Keywords: Gastric cancer; Immunohistochemistry; Meta-analysis; Prognosis; β-catenin.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flowchart showing selection of studies for inclusion in the meta-analysis. IHC: Immunohistochemistry.
Figure 2
Figure 2
Meta-analysis of the effects of β-catenin on overall survival of patients with gastric cancer. Results are presented as individual and pooled HR and 95%CI.
Figure 3
Figure 3
Subgroup analysis of HR for the association of β-catenin expression with overall survival using different definitions.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90. - PubMed
    1. Tsugane S, Sasazuki S. Diet and the risk of gastric cancer: review of epidemiological evidence. Gastric Cancer. 2007;10:75–83. - PubMed
    1. Brenner H, Arndt V, Stürmer T, Stegmaier C, Ziegler H, Dhom G. Individual and joint contribution of family history and Helicobacter pylori infection to the risk of gastric carcinoma. Cancer. 2000;88:274–279. - PubMed
    1. Amedei A, Benagiano M, della Bella C, Niccolai E, D’Elios MM. Novel immunotherapeutic strategies of gastric cancer treatment. J Biomed Biotechnol. 2011;2011:437348. - PMC - PubMed
    1. Micalizzi DS, Farabaugh SM, Ford HL. Epithelial-mesenchymal transition in cancer: parallels between normal development and tumor progression. J Mammary Gland Biol Neoplasia. 2010;15:117–134. - PMC - PubMed